BUSINESS SEGMENT INFORMATION

9 Months Ended

Sep. 30, 2014

Segment Reporting [Abstract]

Business Segment Information [Text Block]

BUSINESS SEGMENT INFORMATION

BMS operates in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. A global research and development organization and supply chain organization are utilized and responsible for the development and delivery of products to the market. Regional commercial organizations distribute and sell the products. The business is also supported by global corporate staff functions. Segment information is consistent with the financial information regularly reviewed by the chief executive officer for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting future periods.

Product revenues were as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
Dollars in Millions	2014		2013		2014		2013
Virology
Baraclude (entecavir)(a)	$	325	$	378	$	1,100	$	1,115
Hepatitis C Franchise(b)	49		—		49		—
Reyataz (atazanavir sulfate)	338		375		1,044		1,167
Sustiva (efavirenz) Franchise(c)	357		389		1,037		1,187
Oncology
Erbitux* (cetuximab)	187		183		542		516
Opdivo (nivolumab)(d)	1		—		1		—
Sprycel (dasatinib)	385		316		1,095		915
Yervoy (ipilimumab)	350		238		942		700
Neuroscience
Abilify* (aripiprazole)(e)	449		569		1,544		1,654
Immunoscience
Orencia (abatacept)	444		375		1,209		1,047
Cardiovascular
Eliquis (apixaban)	216		41		493		75
Diabetes Alliance(f)	42		432		248		1,228
Mature Products and All Other(g)	778		769		2,317		2,340
Total Revenues	$	3,921	$	4,065	$	11,621	$	11,944

*	Indicates brand names of products which are trademarks not owned or wholly owned by BMS. Specific trademark ownership information can be found at the end of this quarterly report on Form 10-Q.
(a)	Includes generic sales of entecavir from a U.S. supply and distribution agreement with Par Pharmaceutical Companies, Inc.
(b)	Includes Daklinza (daclatasvir) revenues of $38 million for the three and nine months ended September 30, 2014, and includes Sunvepra (asunaprevir) revenues of $11 million for the three and nine months ended September 30, 2014.
(c)	Includes alliance and other revenue of $309 million and $328 million for the three months ended September 30, 2014 and 2013, respectively, and $894 million and $998 million for the nine months ended September 30, 2014 and 2013, respectively.
(d)	Includes alliance and other revenue from our alliance with Ono Pharmaceutical Company Ltd. in Japan.
(e)	Includes alliance and other revenue of $410 million and $464 million for the three months ended September 30, 2014 and 2013, respectively, and $1,350 million and $1,313 million for the nine months ended September 30, 2014 and 2013, respectively.
(f)	Includes Bydureon* (exenatide extended-release for injectable suspension), Byetta* (exenatide), Farxiga*/Xigduo* (dapagliflozin/dapagliflozin and metformin hydrochloride), Onglyza*/Kombiglyze* (saxagliptin/saxagliptin and metformin), Myalept* (metreleptin) and Symlin* (pramlintide acetate). BMS sold its diabetes business to AstraZeneca on February 1, 2014.
(g)	Includes Plavix* (clopidogrel bisulfate) revenues of $44 million and $42 million for the three months ended September 30, 2014 and 2013, respectively, and $137 million and $177 million for the nine months ended September 30, 2014 and 2013, respectively. Additionally, includes Avapro*/Avalide* (irbesartan/irbesartan-hydrochlorothiazide) revenues of $56 million and $71 million for the three months ended September 30, 2014 and 2013, respectively, and $171 million and $173 million for the nine months ended September 30, 2014 and 2013, respectively.